Palisade Bio, Inc.: Business Overview, Financials & Competitive Analysis
Palisade Bio, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biotech with promising PDE4 prodrug platform targeting large IBD market, but execution and funding risks remain elevated. Palisade Bio demonstrates promising early clinical data and a differentiated prodrug platform addressing a large IBD market, but faces typical clinical-stage risk including significant cash burn, development timelines, and regulatory approval.
What is Palisade Bio, Inc.'s industry? Palisade Bio, Inc. (palisadebio.com) operates in Immunology Drugs. AskCyborg classifies Palisade Bio, Inc. under Immunology Drugs in its company registry.
Palisade Bio is a clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, with its lead candidate PALI-210...
Cyborg Score thesis
Clinical-stage biotech with promising PDE4 prodrug platform targeting large IBD market, but execution and funding risks remain...
Read the full analyst-debate transcript →Get the Latest Palisade Bio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePalisade Bio, Inc. Overview
Pro stress-test →Palisade Bio is a clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, with its lead candidate PALI-2108 in phase 1b clinical trials to treat inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases through its differentiated prodrug platform and precision pharmacology strategy.
Strategic Profile
Pro stress-test →PALI-2108 is designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. Clinical data from the Phase 1b cohort in moderate-to-severe ulcerative colitis patients showed 100% achieved clinical response and 40% achieved clinical remission, with no serious adverse events; the company is advancing toward Phase 2 clinical studies in UC designed to evaluate clinical remission and response over 12 weeks.
Competitive Landscape
Pro stress-test →Palisade Bio competes in the inflammatory bowel disease therapeutics space against established PDE4 inhibitors and other immunomodulatory agents, positioning PALI-2108 as a novel-formulated alternative with targeted colon delivery and improved tolerability. Competitors include Gilead Sciences (Otezla/apremilast), Pfizer, AbbVie, and other IBD/immunology-focused biopharmaceutical companies developing advanced anti-inflammatory therapeutics.
Industry Context
Palisade Bio, Inc. operates in Immunology Drugs.
Key facts
Founded: 2001 · Headquarters: Denver, Colorado · Employees: Unknown · Revenue: Minimal (clinical-stage) · Market cap: $311M